文献速递细菌感染、耐药与抗菌药物

泰地唑胺治疗囊性纤维化患者金黄色葡萄球菌感染的潜力

Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究评估泰地唑胺对来自美国三个囊性纤维化中心的330株金黄色葡萄球菌的体外和体内活性,并预测耐药选择可能性。泰地唑胺对MRSA和MSSA的MIC90均为0.12-0.25 mg/L,在小鼠肺炎模型中显著降低肺内细菌负荷,且耐药潜力低。结果表明泰地唑胺是治疗囊性纤维化相关MRSA/MSSA感染的有前景的选择。

要点

  • 泰地唑胺对囊性纤维化来源的金黄色葡萄球菌有较强体外活性。
  • 小鼠肺炎模型中泰地唑胺降低肺内细菌负荷优于对照。
  • 泰地唑胺耐药选择潜力低,但需关注MIC高于折点菌株。

核心结论

  • 泰地唑胺是治疗囊性纤维化相关MRSA/MSSA感染的有前景的选择,具有强体内活性和低耐药潜力。

研究设计与样本

  • 研究使用了来自美国三个囊性纤维化中心的330株金黄色葡萄球菌(来自成人和儿童患者),包括正常表型和小菌落变异型。
  • 采用肉汤微量稀释法、Etest和时间-杀菌分析评估泰地唑胺活性,并在小鼠肺炎模型中测试体内疗效。
  • 通过40天暴露和连续传代获得泰地唑胺体外突变株,并对敏感性降低的临床菌株进行全基因组测序。

主要发现

  • MRSA菌株的MIC90:泰地唑胺0.12-0.25 mg/L,利奈唑胺1-2 mg/L;MSSA菌株的MIC90:泰地唑胺0.12 mg/L,利奈唑胺1-2 mg/L。
  • 两株菌(WIS 441和Seattle 106)的泰地唑胺MIC分别为2 mg/L和1 mg/L,高于FDA泰地唑胺折点(0.5 mg/L)。
  • 泰地唑胺在游离血清浓度下表现出抑菌效果。
  • WIS 423感染小鼠肺内平均细菌负荷(log10 cfu/g):对照组11.2±0.5;泰地唑胺组(10 mg/kg)3.40±1.87;利奈唑胺组(40 mg/kg)4.51±2.1;万古霉素组(30 mg/kg)5.21±1.93。
  • WIS 441感染小鼠的相应值(log10 cfu/g):对照组9.66±0.8;泰地唑胺组3.18±1.35;利奈唑胺组5.94±2.19;万古霉素组4.35±1.7。

关键数值与推荐

  • 泰地唑胺对MRSA和MSSA的MIC90为0.12-0.25 mg/L,利奈唑胺为1-2 mg/L。
  • FDA泰地唑胺折点为0.5 mg/L,两株临床菌MIC高于此值。
  • 小鼠肺炎模型中泰地唑胺10 mg/kg降低肺内细菌负荷优于利奈唑胺40 mg/kg和万古霉素30 mg/kg。

临床怎么用

  • 泰地唑胺可作为囊性纤维化患者MRSA/MSSA肺部感染的潜在治疗选择。
  • 临床使用前应关注菌株对泰地唑胺的敏感性,MIC高于0.5 mg/L时需谨慎。

局限性

  • 研究为体外和动物模型,尚未在囊性纤维化患者中进行临床疗效验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tedizolid is a protein synthesis inhibitor in clinical use for the treatment of Gram-positive infections. Pulmonary MRSA infections are a growing problem in patients with cystic fibrosis (CF) and the efficacy of tedizolid-based therapy in CF pulmonary infections is unknown. OBJECTIVES: To evaluate the in vitro and in vivo activity of tedizolid and predict the likelihood of tedizolid resistance selection in CF-background Staphylococcus aureus strains. METHODS: A collection of 330 S. aureus strains (from adult and paediatric patients), either of normal or small colony variant (SCV) phenotypes, gathered at three CF centres in the USA was used. Tedizolid activity was assessed by broth microdilution, Etest and time-kill analysis. In vivo tedizolid efficacy was tested in a murine pneumonia model. Tedizolid in vitro mutants were obtained by 40 days of exposure and progressive passages. Whole genome sequencing of clinical S. aureus strains with reduced susceptibility to tedizolid was performed. RESULTS: MRSA strain MIC90s were tedizolid 0.12-0.25 mg/L and linezolid 1-2 mg/L; for MSSA strains, MIC90s were tedizolid 0.12 mg/L and linezolid 1-2 mg/L. Two strains, WIS 441 and Seattle 106, with tedizolid MICs of 2 mg/L and 1 mg/L, respectively, had MICs above the FDA tedizolid breakpoint (0.5 mg/L). Tedizolid at free serum concentrations exhibited a bacteriostatic effect. Mean bacterial burdens in lungs (log10 cfu/g) for WIS 423-infected mice were: control, 11.2±0.5; tedizolid-treated (10 mg/kg), 3.40±1.87; linezolid-treated (40 mg/kg), 4.51±2.1; and vancomycin-treated (30 mg/kg), 5.21±1.93. For WIS 441-infected mice the (log10 cfu/g) values were: control, 9.66±0.8; tedizolid-treated, 3.18±1.35; linezolid-treated 5.94±2.19; and vancomycin-treated, 4.35±1.7. CONCLUSIONS: These results suggest that tedizolid represents a promising therapeutic option for the treatment of CF-associated MRSA/MSSA infections, having potent in vivo activity and low resistance potential.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Roch M, Varela MC, Taglialegna A, et al. Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients. J Antimicrob Chemother. 2020. PMID: 31617901. doi:10.1093/jac/dkz418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。